Apella Capital LLC Has $571,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Apella Capital LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 58.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,367 shares of the biopharmaceutical company’s stock after acquiring an additional 3,454 shares during the quarter. Apella Capital LLC’s holdings in Bristol-Myers Squibb were worth $571,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BMY. LaFleur & Godfrey LLC lifted its stake in Bristol-Myers Squibb by 3.5% in the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,487 shares during the period. Brighton Jones LLC lifted its stake in Bristol-Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the period. Spire Wealth Management lifted its stake in Bristol-Myers Squibb by 4.3% in the fourth quarter. Spire Wealth Management now owns 18,338 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 760 shares during the period. GDS Wealth Management acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $206,000. Finally, Optas LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $259,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.2%

NYSE:BMY opened at $48.01 on Thursday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a 50-day simple moving average of $49.82 and a 200 day simple moving average of $55.19. The company has a market cap of $97.70 billion, a PE ratio of -10.86, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business’s revenue was down 5.6% compared to the same quarter last year. During the same period last year, the company earned ($4.40) earnings per share. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares of the company’s stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Argus raised Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Piper Sandler initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price on the stock. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $58.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.